For example, sequential administration ofboth diagnostic agents at an interval of 3 days before the start of systemictherapy in 11 HER2-positive BC patients demonstrated a higher uptake of[99mTc]Tc-ADAPT6 by primary breast tumors (SUVmax = 4.7 ± 2.1) 2 h afteradministration compared with that of [99mTc]Tc-(HE)3-G3(SUVmax = 3.5 ± 1.7) 4 h after administration (p <0.005, paired t-test). This evidence concerns the gene ERBB2 and breast cancer.